{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T14:36:26Z","timestamp":1754145386321,"version":"3.41.2"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.rdc.2025.05.006","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T23:56:14Z","timestamp":1748994974000},"page":"483-494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Challenges in Developing Treatment Guidelines in Psoriatic Arthritis"],"prefix":"10.1016","volume":"51","author":[{"given":"Larabe","family":"Farrukh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Kavanaugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2011","series-title":"Clinical practice guidelines we can trust","key":"10.1016\/j.rdc.2025.05.006_bib1"},{"issue":"8","key":"10.1016\/j.rdc.2025.05.006_bib2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrrheum.2009.146","article-title":"Guidelines in rheumatology: quo vadis?","volume":"5","author":"Kavanaugh","year":"2009","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"10.1016\/j.rdc.2025.05.006_bib3","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrrheum.2010.138","article-title":"Guidelines for RA therapy\u2014avoiding hamartia","volume":"6","author":"Kavanaugh","year":"2010","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.006_bib4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/2475530318812244","article-title":"2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis","volume":"4","author":"Singh","year":"2019","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"8","key":"10.1016\/j.rdc.2025.05.006_bib5","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.006_bib6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","article-title":"Psoriatic arthritis","volume":"7","author":"FitzGerald","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"19","key":"10.1016\/j.rdc.2025.05.006_bib7","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"10136","key":"10.1016\/j.rdc.2025.05.006_bib8","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.rdc.2025.05.006_bib9","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1136\/annrheumdis-2018-215003","article-title":"The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies","volume":"78","author":"Kavanaugh","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"Supplement_1","key":"10.1016\/j.rdc.2025.05.006_bib10","doi-asserted-by":"crossref","first-page":"i37","DOI":"10.1093\/rheumatology\/kez383","article-title":"Treatment guidelines in psoriatic arthritis","volume":"59","author":"Ogdie","year":"2020","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.rdc.2025.05.006_bib11","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2014results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.006_bib12","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1186\/s13063-022-06589-y","article-title":"Efficacy and safety of guselkumab in biologic-na\u00efve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial","volume":"23","author":"Gladman","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.rdc.2025.05.006_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211057975","article-title":"Axial involvement in psoriatic arthritis cohort (AXIS): the protocol of a joint project of the assessment of SpondyloArthritis international society (ASAS) and the group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA)","volume":"13","author":"Poddubnyy","year":"2021","journal-title":"Therapeutic advances in musculoskeletal disease"},{"issue":"6","key":"10.1016\/j.rdc.2025.05.006_bib14","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41584-018-0006-8","article-title":"Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison","volume":"14","author":"Feld","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"10.1016\/j.rdc.2025.05.006_bib15","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41584-022-00810-7","article-title":"Sex-and gender-related differences in psoriatic arthritis","volume":"18","author":"Tarannum","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2025.05.006_bib16","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.rdc.2025.05.006_bib17","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction\u2014GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"10.1016\/j.rdc.2025.05.006_bib18","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2025.05.006_bib19","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.rdc.2025.05.006_bib20","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.rdc.2022.03.008","article-title":"The evaluation of guideline quality in rheumatic diseases","volume":"48","author":"Barber","year":"2022","journal-title":"Rheum Dis Clin"},{"issue":"2","key":"10.1016\/j.rdc.2025.05.006_bib21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40744-022-00514-0","article-title":"Sequencing of biologic and target synthetic disease-modifying anti-rheumatic drugs in psoriatic arthritis: are we ready to redefine the treatment strategy? A perspective","volume":"10","author":"Lubrano","year":"2023","journal-title":"Rheumatology and Therapy"},{"issue":"16","key":"10.1016\/j.rdc.2025.05.006_bib22","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s40265-018-0994-3","article-title":"Tapering and discontinuation of biologics in patients with psoriatic arthritis with low disease activity","volume":"78","author":"Ye","year":"2018","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.rdc.2025.05.006_bib23","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00296-020-04775-2","article-title":"Comorbidities in psoriatic arthritis: a systematic review and meta-analysis","volume":"41","author":"Gupta","year":"2021","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.006_bib24","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3390\/ijms19010058","article-title":"Cardiometabolic comorbidities in psoriasis and psoriatic arthritis","volume":"19","author":"Puig","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.rdc.2025.05.006_bib25","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41584-022-00767-7","article-title":"Oral surveillance and JAK inhibitor safety: the theory of relativity","volume":"18","author":"Winthrop","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.006_bib26","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/ard-2022-223297","article-title":"Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS\/EULAR recommendations for the management of axial spondyloarthritis","volume":"82","author":"Ortolan","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.006_bib27","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41392-023-01655-6","article-title":"Signaling pathways and targeted therapies for psoriasis","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.rdc.2025.05.006_bib28","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00403-018-1808-x","article-title":"Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review","volume":"310","author":"Florek","year":"2018","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"10.1016\/j.rdc.2025.05.006_bib29","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1177\/24755303241253200","article-title":"Patients\u2019 preferences regarding modes of systemic psoriasis treatment - a qualitative study","volume":"9","author":"Zaino","year":"2024","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"10.1016\/j.rdc.2025.05.006_bib30","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40273-018-0618-5","article-title":"Cost and cost effectiveness of treatments for psoriatic arthritis: a systematic literature review","volume":"36","author":"Angiolella","year":"2018","journal-title":"Pharmacoeconomics"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X25000298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X25000298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:15:14Z","timestamp":1752711314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X25000298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0889857X25000298"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2025.05.006","relation":{},"ISSN":["0889-857X"],"issn-type":[{"type":"print","value":"0889-857X"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges in Developing Treatment Guidelines in Psoriatic Arthritis","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2025.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}